Pomerantz Law Firm Explores Legal Claims for REGENXBIO Investors Amid Clinical Hold by FDA

Investigating Claims Against REGENXBIO Inc.

Pomerantz LLP, a distinguished law firm, is currently probing potential legal claims on behalf of investors of REGENXBIO Inc. (NASDAQ: RGNX). This investigation arises in the wake of troubling revelations regarding the company’s investigational gene therapies, RGX-111 and RGX-121, which have recently encountered a major setback.

On January 28, 2026, REGENXBIO made headlines when it disclosed in a press release that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on both RGX-111, aimed at treating MPS I (Hurler syndrome), and RGX-121, intended for MPS II (Hunter Syndrome). This unexpected news stemmed from an unfortunate incident involving a participant in the Phase I/II study for RGX-111, who experienced a neoplasm in their central nervous system.

Due to the interconnected risk factors associated with both gene therapy studies, the FDA's hold signifies serious concerns about the safety and efficacy of the treatments. Following this announcement, REGENXBIO's stock plummeted by $2.40, equating to a significant 17.9% drop, closing at $11.01 per share. Such drastic movements in stock prices often trigger investigations as stakeholders seek to ascertain whether fraudulent practices or other unethical behaviors may have influenced this unfavorable turn of events.

Danielle Peyton, a representative of Pomerantz LLP, has urged affected investors to come forward to discuss their experiences. In legal circles, the firm has built a reputation for effectively championing the rights of investors who have faced significant financial losses due to corporate misconduct, securities fraud, and breaches of fiduciary duty. With a storied history of over 85 years, Pomerantz is considered one of the pioneers in the field of securities class actions.

Founded by the prominent figure Abraham L. Pomerantz, the firm has consistently fought to recover damages for victims of securities fraud. They have successfully secured numerous multimillion-dollar settlements for their clients across various high-profile class-action cases. This current investigation into REGENXBIO aligns with the firm’s mission to ensure accountability and justice in the corporate sector.

As the investigation continues, potential investors and involved parties are encouraged to closely monitor developments concerning REGENXBIO and to reach out to Pomerantz LLP for guidance. Investors are advised to consider the implications of this investigation, along with the inherent risks of participation in clinical research programs, and stay informed about the company’s ongoing dealings with regulatory bodies.

In summary, the actions taken by the FDA pose significant questions regarding REGENXBIO's future, particularly as the company navigates this ongoing regulatory scrutiny. Investors are advised to remain vigilant and proactive in safeguarding their interests during this tumultuous period.

For further inquiries and detailed information regarding the potential class action, affected investors can contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.